OXURION NV (OXUR.BR) Stock Overview
Europe - EBR:OXUR - BE0974487192 - Common Stock
OXUR.BR Key Statistics, Chart & Performance
The current stock price of OXUR.BR is 0.0148 EUR. In the past month the price decreased by -21.28%. In the past year, price decreased by -94.91%.
OXUR.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.49 | 346.25B | ||
| AMG.DE | AMGEN INC | 13.42 | 135.69B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.56 | 128.80B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.3 | 94.65B | ||
| ARGX.BR | ARGENX SE | 94.35 | 43.22B | ||
| 1AE.DE | ARGENX SE | 94.35 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.84B | ||
| IDP.DE | BIOGEN INC | 9.4 | 19.01B | ||
| 1EXEL.MI | EXELIXIS INC | 17.25 | 8.26B | ||
| 0QF.DE | MODERNA INC | N/A | 9.01B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.85B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.17B |
Related stock screener links
About OXUR.BR
Company Profile
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Leuven (Louvain), Vlaams-Brabant and currently employs 11 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
Company Info
OXURION NV
Gaston Geenslaan 1
LEUVEN (LOUVAIN) VLAAMS-BRABANT BE
Employees: 11
Phone: 3216751310
OXURION NV / OXUR.BR FAQ
What does OXURION NV do?
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Leuven (Louvain), Vlaams-Brabant and currently employs 11 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
What is the stock price of OXURION NV today?
The current stock price of OXUR.BR is 0.0148 EUR. The price decreased by -1.33% in the last trading session.
What is the dividend status of OXURION NV?
OXUR.BR does not pay a dividend.
What is the ChartMill rating of OXURION NV stock?
OXUR.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does OXURION NV belong to?
OXURION NV (OXUR.BR) operates in the Health Care sector and the Biotechnology industry.
When does OXURION NV (OXUR.BR) report earnings?
OXURION NV (OXUR.BR) will report earnings on 2026-04-03, after the market close.
Can you provide the ownership details for OXUR stock?
You can find the ownership structure of OXURION NV (OXUR.BR) on the Ownership tab.
OXUR.BR Technical Analysis
OXUR.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OXUR.BR. OXUR.BR may be in some trouble as it scores bad on both profitability and health.
OXUR.BR Financial Highlights
Over the last trailing twelve months OXUR.BR reported a non-GAAP Earnings per Share(EPS) of 0.61. The EPS increased by 101.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 97950% | ||
| ROA | 39.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |